This link between IDH and PSMA status, might on the one hand, open a new way of looking at glioma characterization based on biomarker evaluation in glioma tissue samples in relation to prognosis and, on the other hand, open up new theranostic perspectives by implementing radioactively labeled PSMA ligands in the therapeutic management of glioma. Here, IDH1 is linked to glioma.